Webinars, Pharmaceutical

Nose to Brain Drug Delivery – A Promising Future

Nose to brain drug delivery has considerable potential to address currently unmet needs for CNS therapeutics for the treatment of disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis.

This webinar discusses the mechanisms of drug delivery to the CNS, drug delivery technology considerations, and formulation ingredients and strategies, including an examination of the pros and cons of liquid vs. powder formulation. By bypassing the blood brain barrier, nose to brain drug delivery offers potential to deliver different drugs and lower doses with minimal systemic effect. The criticality of successful targeting of the olfactory region is noted and the beneficial role of excipients such as mucoadhesives and penetration enhancers is outlined.

Aptar Pharma’s expertise in all aspects of the development and reformulation of drugs for nose to brain delivery is highlighted.

Watch the webinar
Speaker(s): Reenal Gandhi Gemma Budd
22 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

26 May 2020

Aptar Pharma discusses Article 117 of the Medical Device Regulations

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
12 May 2020

Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions, Innovation & Insights

Read More
1 May 2020

Supporting Improved Patient Onboarding and Adherence with Training Solutions

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
21 Apr 2020

Using in vitro dissolution tests for local bioequivalence in OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights

Read More
1 21 22 23 24 25 27

Request Access

Close

Requesting access to Nose to Brain Drug Delivery – A Promising Future.

  • This field is for validation purposes and should be left unchanged.
Back To Top